Table 1.
Baseline characteristics of patients with class V+IV LNa
| Characteristic | Multitarget Therapy Group (n = 20) | IVCY Group (n = 20) | P |
|---|---|---|---|
| Male:female | 4:16 | 2:18 | 0.657 |
| Biopsy age (yr; mean ± SD) | 27.2 ± 7.1 | 30.6 ± 4.6 | 0.084 |
| Duration of SLE (mo) | 36.0 (12.7 to 72.0) | 44.0 (4.7 to 78.0) | 0.924 |
| Duration of LN (mo) | 30.0 (4.5 to 60.0) | 26.0 (3.7 to 58.7) | 0.692 |
| SLE-DAI (mean ± SD) | 14.9 ± 4.0 | 14.0 ± 2.4 | 0.401 |
| Urine protein (g/24 h; mean ± SD) | 4.41 ± 1.95 | 4.10 ± 1.20 | 0.554 |
| Urine RBC (×104/ml) | 37.5 (3.5 to 106.2) | 40.0 (10.0 to 161.2) | 0.945 |
| Scr (mg/dl; mean ± SD) | 0.87 ± 0.21 | 0.89 ± 0.30 | 0.797 |
| eCcr (ml/min per 1.73 m2; mean ± SD) | 98.6 ± 23.5 | 96.6 ± 26.3 | 0.795 |
| Renal insufficiency (Scr >1.24 mg/dl; n [%]) | 1 (5.0) | 2 (10.0) | 1.000 |
| Albumin (g/L; mean ± SD) | 23.9 ± 5.7 | 24.6 ± 3.9 | 0.665 |
| ANA positive (n [%]) | 18 (90.0) | 19 (95.0) | 1.000 |
| Anti-dsDNA positive (n [%]) | 12 (60.0) | 12 (60.0) | 1.000 |
| Serum C3 <0.79 g/L (n [%]) | 20 (100.0) | 19 (95.0) | 1.000 |
| Pathological active index (mean ± SD) | 9.8 ± 4.2 | 8.0 ± 3.7 | 0.148 |
| Pathological chronic index (mean ± SD) | 1.3 ± 0.8 | 1.4 ± 0.7 | 0.687 |
| Proportion of glomeruli affected by proliferative lesions (%, mean ± SD) | 96.1 ± 6.4 | 93.2 ± 9.9 | 0.293 |
| Proportion of glomeruli affected by membranous lesions (involving >50% of the tuft; %, mean ± SD) | 59.8 ± 6.6 | 60.1 ± 7.3 | 0.893 |
| Previous treatment with CTX or MMF (n [%]) | 14 (70.0) | 12 (60.0) | 0.507 |
| ACEI or ARB used (n [%]) | 9 (45.0) | 11 (55.0) | 0.527 |
a
ACEI, angiotensin-converting enzyme inhibitor; ANA, antinuclear antibody; ARB, angiotensin II receptor blocker; DAI, disease active index; eCcr, estimated creatinine clearance rate; Scr, serum creatinine.